Scientific opinion on the safety of selenite triglycerides as a source of selenium added for nutritional purposes to food supplements.
bioavailability
food supplement
novel food
nutrient source
safety
selenite triglycerides
selenium
Journal
EFSA journal. European Food Safety Authority
ISSN: 1831-4732
Titre abrégé: EFSA J
Pays: United States
ID NLM: 101642076
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
epublish
Résumé
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on selenite triglycerides as a novel food (NF) pursuant to Regulation (EU) 2015/2283, their safety when added for nutritional purposes to food supplements as a source of selenium and the bioavailability of selenium from this source, in the context of Directive 2002/46/EC. The proposed NF is the first lipophilic organic form of selenium so far described in the literature. It is composed by a mixture of individual Se-containing lipids which do not occur in nature. The Panel considers that the information provided on the composition of the NF does not allow a complete characterisation of the product. From the data provided to characterise the absorption, distribution, metabolism and excretion of the NF, it cannot be established in which chemical form Se is systemically available and if it can enter the functional Se body pool to fulfil Se physiological functions. The Panel considers that, since it is not demonstrated that the NF is converted to a known form of Se following ingestion and absorption, the NF is to be treated as a xenobiotic with unknown properties in the body. From a subchronic toxicity study in rats, the Panel derives a lowest observed adverse effect level (LOAEL) for general toxicity of 2 mg Se/kg body weight (bw) per day based on findings indicating liver as a target organ, as it has been shown for other studies on dietary Se. The Panel concludes that the NF is absorbed and provides Se, but in an unknown form of which the bioavailability has not been determined. The Panel also concludes that the safety of the NF under the intended conditions of use cannot be established.
Identifiants
pubmed: 32874319
doi: 10.2903/j.efsa.2020.6134
pii: EFS26134
pmc: PMC7448081
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e06134Informations de copyright
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.
Références
EFSA J. 2018 Jun 26;16(6):e05294
pubmed: 32625933
Drugs Exp Clin Res. 1997;23(1):7-11
pubmed: 9093817
Mutat Res. 2010 Jun 17;699(1-2):44-6
pubmed: 20417718
Pharmacol Rep. 2018 Dec;70(6):1073-1078
pubmed: 30296743
Antioxid Redox Signal. 2011 Apr 1;14(7):1337-83
pubmed: 20812787
Food Chem Toxicol. 2018 May;115:482-490
pubmed: 29621579
J Agric Food Chem. 2016 Jun 22;64(24):4975-81
pubmed: 27214173
Drugs Exp Clin Res. 1995;21(6):217-20
pubmed: 8907696
Sci Total Environ. 2020 Jun 1;719:134541
pubmed: 31862262
Sci Total Environ. 2013 Jan 15;443:633-42
pubmed: 23220755
Pharmacol Rep. 2015 Feb;67(1):1-8
pubmed: 25560568
Nutrients. 2019 Jul 04;11(7):
pubmed: 31277500
J Pharm Biomed Anal. 2003 Aug 8;32(4-5):1029-36
pubmed: 12899990